Drug intelligence / Profile preview

KGX-106

Development stage: Preclinical
Lead developer: Shanghai Kangkang Biotechnology
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

KGX-106 is a bispecific T-cell engager (BiTE) drug candidate developed by Shanghai Kangkang Biotechnology. It targets the CD3 molecule on T cells, acting as a CD3 stimulant to activate and redirect T cells against tumor cells. The primary therapeutic area for KGX-106 is oncology, specifically for the treatment of solid tumors. As of April 2025, its highest development phase is preclinical, with no reported clinical trial results or regulatory approvals yet[1][2].

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on KGX-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KGX-106.

Explore the full profile